BL M11D1
Alternative Names: BL-M11D1; BL-M11D1-ADCLatest Information Update: 15 Jun 2024
At a glance
- Originator Sichuan Baili Pharmaceutical
- Class Antibodies; Antineoplastics; Camptothecins; Drug conjugates; Immunoconjugates
- Mechanism of Action Antibody-dependent cell cytotoxicity; DNA topoisomerase I inhibitors; Immunologic cytotoxicity
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Acute myeloid leukaemia
Most Recent Events
- 05 Apr 2024 Pharmacodynamics data from a preclinical study in Acute myeloid leukaemia presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
- 31 Aug 2023 Phase-I clinical trials in Acute myeloid leukaemia (Second-line therapy or greater) in China (IV) (NCT05924750)
- 29 Jun 2023 Sichuan Baili Pharmaceutical plans a phase I trial for Acute myeloid leukaemia (Second-line therapy or greater) in China (IV, Infusion), in August 2023 (NCT05924750)